Description

(Triple Agonist: GLP-1R / GIPR / GCGR)

GLP-1-R is a novel synthetic peptide developed as a triple agonist targeting the receptors for glucagon-like peptide-1 (GLP-1R), glucose-dependent insulinotropic polypeptide (GIPR), and glucagon (GCGR). This multi-receptor approach has been investigated in preclinical and clinical studies for its potential to enhance energy expenditure, improve glucose metabolism, and promote significant weight modulation in research models.

By simultaneously engaging these three metabolic pathways, Retatrutide has attracted scientific interest as a next-generation incretin-based therapeutic candidate in metabolic and obesity research.

---

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1R activation: Enhances insulin secretion, delays gastric emptying, and reduces appetite

• GIPR activation: Complements GLP-1 action, supporting insulin sensitivity and glucose regulation

• GCGR activation: Increases energy expenditure and promotes fat metabolism through mild glucagon signaling

• Integrates multiple hormonal axes to drive metabolic adaptations beyond single-pathway agonists

---

Potential Benefits (Based on Preclinical Research):

• Significant reductions in body weight in obesity research models

• Improved glycemic control and insulin sensitivity

• Enhanced energy expenditure and fat oxidation

• Studied for cardiometabolic benefits, including lipid regulation

• Potential applications in research exploring triple-incretin modulation

---

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.